Startup profile · funding coverage
AvenCell Therapeutics funding, valuation and investors
Clinical-stage allogeneic CAR-T company that entered a financing agreement with Ligand worth up to $47 million.
Keep track of AvenCell Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Royalty financing + Series C equity
Up to $47M total ($41M royalty + $6M equity) · September 24, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth
Investors in latest funding
Lead: Ligand Pharmaceuticals
Overview
AvenCell Therapeutics develops controllable allogeneic CAR-T therapies. On September 24, 2026 Ligand Pharmaceuticals disclosed a financing agreement worth up to $47 million: up to $41 million in milestone-based royalty financing and up to $6 million in concomitant Series C equity financing.
Why AvenCell Therapeutics is interesting
The financing is structurally unusual: up to $41M of royalty financing plus up to $6M of Series C equity, not a plain $47M venture round.
Key facts
- Sep 24, 2026: up to $47M financing agreement
- Up to $41M is royalty financing; up to $6M is Series C equity
Funding history (newest first)
Royalty financing + Series C equity
2026-09-24 Up to $47M total ($41M royalty + $6M equity)- Ligand Pharmaceuticals (lead)
Source: https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd_avencellreleasex20260.htm
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.